查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
大分子CDMO市场规模、份额、趋势分析报告:按服务（合同製造、合同开发）、供应商、最终用户、地区、细分市场，2023-2030 年
市场调查报告书
商品编码
1171057

大分子CDMO市场规模、份额、趋势分析报告:按服务（合同製造、合同开发）、供应商、最终用户、地区、细分市场，2023-2030 年

Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report By Service (Contract Manufacturing, Contract Development), By Source, By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 145 Pages | 商品交期: 2-10个工作天内

价格

大分子药物CDMO的市场增长及趋势

到 2030 年，全球大分子 CDMO 市场规模预计将达到 221 亿美元，2023 年至 2030 年的复合年增长率为 9.3%。 传染病发病率上升和对新型治疗药物的高需求是推动市场的主要因素。

合同製造是大分子药物製造的关键步骤之一，占大分子药物市场的很大一部分。 製造形式是一个需要考虑的重要因素，因为它代表了该领域的外包或内部活动。 由于高成本和时间延迟，公司现在选择外包服务。 因此，公司将大部分大分子外包出去。 CDMO（合同开发和製造组织）是一家为製药行业提供从药物开发到製造的综合服务的公司。 CDMO 通过引入第三方项目并提供他们的知识、开发和製造能力来提供重要服务。

在 COVID-19 大流行之前，大量新的治疗方案导致对大分子药物的投资增加。 在开发针对 SARS-CoV-2 病毒的疗法和疫苗的竞赛中，出现了对生物製剂的评估。 特别是CDMOs对大批量、高质量CGMP原料药和药品生产服务的需求急剧增加，CDMOs可以提供广泛的COVID疫苗技术和治疗性单克隆抗体产品。

大分子 CDMO 市场报告要点

到2022年，合同製造服务领域将以超过65.0%的销售额占据市场主导地位

按供应来源划分，2022 年哺乳动物部分占比最大，超过 55.0%。 随着更复杂的生物製剂的发展，例如双特异性和三特异性抗体以及抗体-药物偶联物，这一类别将扩大。

到 2022 年，按最终用户划分，生物技术公司将占据最大份额，超过 40.0%。 企业加大大分子研发投入驱动市场

亚太地区预计在预测期内实现 10.4% 的复合年增长率最快。 高患者人数、低成本、熟练劳动力和不断变化的监管情景是市场扩张的主要驱动力

内容

第1章调查方法及范围

  • 市场细分和范围
    • 服务
    • 来源
    • 最终用户
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 初步调查的详细信息
      • 来自北美主要访谈的数据
      • 来自欧洲主要访谈的数据
      • 来自亚太地区主要访谈的数据
      • 来自拉丁美洲主要访谈的数据
      • 来自关于 Mea 的主要访谈的数据
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 模型详细信息
    • 商品流分析（模型 1）
      • 方法 1:商品流方法
    • 批量价格分析（模型 2）
      • 方法 2:量价分析
  • 二级信息列表
  • 主要信息列表
  • 缩写列表

第 2 章执行摘要

  • 市场前景

第 3 章大分子 CDMO 市场:变量、趋势和范围

  • 市场系列展望
    • 母公司的市场前景
    • 辅助市场展望
  • 市场变量分析
    • 市场驱动因素分析
      • 增加对大分子药物的批准
      • 传染病发病率增加，
      • 製药和生物技术公司增加对先进技术的资本投资，以与 CDMO 建立合作伙伴关係
    • 市场製约因素分析
      • 外包期间的合规问题
      • 新兴国家国内情景的变化
  • 大分子 CDMO 市场:分析工具
    • 波特的五力分析
    • PESTEL 分析
    • 对主要交易和战略联盟的分析
      • 併购
      • 分机
      • 合同和合作
  • COVID-19 影响和改革分析

第 4 章大分子 CDMO 市场:服务细分分析

  • 大分子 CDMO 市场:定义和范围
  • 大分子 CDMO 市场:市场份额分析，2022 年和 2030 年
  • 合同製造
    • 临床
    • 商业
  • 委託开发
    • 细胞系的开发
    • 流程开发

第 5 章大分子 CDMO 市场:供应商细分分析

  • 大分子 CDMO 市场:定义和范围
  • 大分子 CDMO 市场:市场份额分析，2022 年和 2030 年
  • 哺乳动物
  • 微生物
  • o其他

第 6 章大分子 CDMO 市场:最终用户细分分析

  • 大分子 CDMO 市场:定义和范围
  • 大分子 CDMO 市场:市场份额分析，2022 年和 2030 年
  • 生物技术公司
  • 首席风险官
  • 其他（製药公司、政府、研究机构、学术机构等）

第 7 章大分子 CDMO 市场:区域分析

  • 区域市场概况
  • 大分子 CDMO 市场:市场份额分析，2022 年和 2030 年
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
    • 亚太地区的其他国家/地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 母马
    • 南非
    • 沙特阿拉伯
    • 你
    • 科威特
    • MEA 的剩余部分

第8章公司简介

  • Thermo Fisher Scientific Inc.
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 欧陆科学
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 药明生物
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 三星生物製品
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 康泰伦特公司
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • Rentschler Biopharma SE
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • AGC 生物製剂
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • Recipharm AB（公共）
    • 公司概况
    • 财务业绩
    • 服务基准
  • 齐格弗里德控股公司
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
  • 勃林格殷格翰
    • 公司概况
    • 服务基准
    • 战略举措
  • FUJIFILM Diosynth Biotechnologies
    • 公司概况
    • 财务业绩
    • 服务基准
    • 战略举措
Product Code: GVR-4-68039-946-2

Large Molecule Drug Substance CDMO Market Growth & Trends:

The global large molecule drug substance CDMO market size is expected to reach USD 22.1 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.3% from 2023 to 2030. Rising incidence of infectious diseases and high demand for novel therapeutics are the key factors driving the market.

Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider because it represents the sector's outsourcing and in-house activities. Companies are now choosing to outsource services due to high costs and delays in time. This has resulted in a greater proportion of large molecules being outsourced by the firms. A contract development and manufacturing organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities.

Prior to the COVID-19 pandemic, large molecule drug investment was increasing as it offers a plethora of new treatment options. The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Large Molecule Drug Substance CDMO Market Report Highlights:

  • The contract manufacturing service segment dominated the market with a revenue share of over 65.0% in 2022
  • Based on source, the mammalian segment accounted for the largest share of over 55.0% in 2022. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody-drug conjugates are evolved
  • Based on end-user, the biotech companies segment accounted for the largest share of over 40.0% in 2022. Rising R&D investment by the firms for large molecules drives the market
  • Asia Pacific is projected to register the fastest CAGR of 10.4% during the forecast period. The large patient base, lower overall costs, skilled workforce, and changes in the regulatory scenario are the key factors driving the market

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 service
    • 1.1.2 Source
    • 1.1.3 End-User
    • 1.1.4 Regional Scope
    • 1.1.5 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data For Primary Interviews In North America
      • 1.3.5.2 Data For Primary Interviews In Europe
      • 1.3.5.3 Data For Primary Interviews In Asia Pacific
      • 1.3.5.4 Data For Primary Interviews In Latin America
      • 1.3.5.5 Data For Primary Interviews In Mea
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.2 Volume Price Analysis (Model 2)
      • 1.6.2.1 Approach 2: Volume Price Analysis
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Large Molecule Drug Substance CDMO Market: Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Market Variable Analysis
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Increasing large molecule drug approvals
      • 3.2.1.2 Rising incidence of infectious diseases,
      • 3.2.1.3 Higher capital investments by pharma and biotech firms in advanced technologies for establishing partnerships with CDMOs
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Compliance issues while outsourcing
      • 3.2.2.2 Changing scenarios within developing countries
  • 3.3 Large Molecule Drug Substance CDMO Market: Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestel Analysis
    • 3.3.3 Major Deals & Strategic Alliances Analysis
      • 3.3.3.1 Mergers And Acquisitions
      • 3.3.3.2 Expansions
      • 3.3.3.3 Agreement & Collaborations
  • 3.4 Covid-19 Impact and Reformation Analysis

Chapter 4 Large Molecule Drug Substance CDMO Market: Service Segment Analysis

  • 4.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • 4.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
  • 4.3 contract Manufacturing
    • 4.3.1 Contract Manufacturing Services Market, 2018 - 2030 (USD Million)
    • 4.3.2 Clinical
      • 4.3.2.1 Clinical, 2018 - 2030 (USD Million)
    • 4.3.3 commercial
      • 4.3.3.1 Commercial market, 2018 - 2030 (USD Million)
  • 4.4 Contract Development
    • 4.4.1 Contract Development Market, 2018 - 2030 (USD Million)
    • 4.4.2 Cell Line Development
      • 4.4.2.1 Cell Line Development Market, 2018 - 2030 (USD Million)
    • 4.4.3 Process Development
      • 4.4.3.1 Process Development Market, 2018 - 2030 (USD Million)

Chapter 5 Large Molecule Drug Substance CDMO Market: Source Segment Analysis

  • 5.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • 5.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
  • 5.3 Mammalian
    • 5.3.1 Mammalian Market, 2018 - 2030 (USD Million)
  • 5.4 Microbial
    • 5.4.1 Microbial Market, 2018 - 2030 (USD Million)
  • 5.5 oOthers
    • 5.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Large Molecule Drug Substance CDMO Market: End-user Segment Analysis

  • 6.1 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • 6.2 Large Molecule Drug Substance CDMO Market: Market Share Analysis, 2022 & 2030
  • 6.3 Biotech Companies
    • 6.3.1 Biotech Companies Market, 2018 - 2030 (USD Million)
  • 6.4 CRO
    • 6.4.1 CRO Market, 2018 - 2030 (USD Million)
  • 6.5 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.)
    • 6.5.1 Others (Pharma Companies, Government, Research Institutes, Academic Institutes, Etc.) Market, 2018 - 2030 (USD Million)

Chapter 7 Large Molecule Drug Substance CDMO Market: Regional Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 Large Molecule Drug Substance Cdmo Market: Market Share Analysis, 2022 & 2030
  • 7.3 North America
    • 7.3.1 North America Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.3.2 U.S.
      • 7.3.2.1 U.S. Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.3.3 Canada
      • 7.3.3.1 Canada Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.4 Europe
    • 7.4.1 Europe Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.2 U.K.
      • 7.4.2.1 U.K. Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.3 Germany
      • 7.4.3.1 Germany Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.4 France
      • 7.4.4.1 France Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.5 Italy
      • 7.4.5.1 Italy Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.6 Spain
      • 7.4.6.1 Spain Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.7 Denmark
      • 7.4.7.1 Denmark Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.8 Sweden
      • 7.4.8.1 Sweden Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.9 Norway
      • 7.4.9.1 Norway Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.4.10 Rest Of Europe
      • 7.4.10.1rest Of Europe Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.5 Asia Pacific
    • 7.5.1 Asia Pacific Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.2 Japan
      • 7.5.2.1 Japan Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.3 China
      • 7.5.3.1 China Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.4 India
      • 7.5.4.1 India Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.5 Australia
      • 7.5.5.1 Australia Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.6 Thailand
      • 7.5.6.1 Thailand Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.7 South Korea
      • 7.5.7.1 South Korea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.5.8 Rest Of Apac
      • 7.5.8.1 Rest Of Apac Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.6 Latin America
    • 7.6.1 Latin America Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.2 Brazil
      • 7.6.2.1 Brazil Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.3 Mexico
      • 7.6.3.1 Mexico Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.4 Argentina
      • 7.6.4.1 Argentina Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.6.5 Rest Of Latam
      • 7.6.5.1 Rest Of Latam Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
  • 7.7 Mea
    • 7.7.1 Mea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.2 South Africa
      • 7.7.2.1 South Africa Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.3 Saudi Arabia
      • 7.7.3.1 Saudi Arabia Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.4 Uae
      • 7.7.4.1 Uae Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.4 Kuwait
      • 7.7.4.1 Kuwait Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)
    • 7.7.4 Rest Of MEA
      • 7.7.4.1 rest Of Mea Large Molecule Drug Substance Cdmo Market, 2018 - 2030 (USD Million)

Chapter 8 Company Profiles

    • 8.1.1 Thermo Fisher Scientific Inc.
      • 8.1.1.1 Company Overview
      • 8.1.1.2 Financial Performance
      • 8.1.1.3 Service Benchmarking
      • 8.1.1.4 Strategic Initiatives
    • 8.1.2 Eurofins Scientific
      • 8.1.2.1 Company Overview
      • 8.1.2.2 Financial Performance
      • 8.1.2.3 Service Benchmarking
      • 8.1.2.4 Strategic Initiatives
    • 8.1.3 WuXi Biologics
      • 8.1.3.1 Company Overview
      • 8.1.3.2 Financial Performance
      • 8.1.3.3 Service Benchmarking
      • 8.1.3.4 Strategic Initiatives
    • 8.1.4 Samsung Biologics
      • 8.1.4.1 Company Overview
      • 8.1.4.2 Financial Performance
      • 8.1.4.3 Service Benchmarking
      • 8.1.4.4 Strategic Initiatives
    • 8.1.5 Catalent, Inc.
      • 8.1.5.1 Company Overview
      • 8.1.5.2 Financial Performance
      • 8.1.5.3 Service Benchmarking
      • 8.1.5.4 Strategic Initiatives
    • 8.1.6 Rentschler Biopharma SE
      • 8.1.6.1 Company Overview
      • 8.1.6.2 Financial Performance
      • 8.1.6.3 Service Benchmarking
      • 8.1.6.4 strategic Initiatives
    • 8.1.7 AGC Biologics
      • 8.1.7.1 Company Overview
      • 8.1.7.2 Financial Performance
      • 8.1.7.3 Service Benchmarking
      • 8.1.7.4 Strategic Initiatives
    • 8.1.8 Recipharm AB (publ)
      • 8.1.8.1 Company Overview
      • 8.1.8.2 Financial Performance
      • 8.1.8.3 Service Benchmarking
    • 8.1.8 Siegfried Holding AG
      • 8.1.8.1 Company Overview
      • 8.1.8.2 Financial Performance
      • 8.1.8.3 Service Benchmarking
      • 8.1.8.4 Strategic Initiatives
    • 8.1.10 Boehringer Ingelheim
      • 8.1.10.1 Company Overview
      • 8.1.10.2 Service Benchmarking
      • 8.1.10.3 Strategic Initiatives
    • 8.1.11 FUJIFILM Diosynth Biotechnologies
      • 8.1.11.1 Company Overview
      • 8.1.11.2 Financial Performance
      • 8.1.11.3 Service Benchmarking
      • 8.1.11.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in Asia Pacific
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Commodity Flow Analysis
  • Fig. 14 Volume Price Analysis
  • Fig. 15 Large Molecule Drug Substance CDMO market snapshot (2022)
  • Fig. 16 Large Molecule Drug Substance CDMO market segmentation
  • Fig. 17 Large Molecule Drug Substance CDMO market: Strategy framework
  • Fig. 18 Parent market outlook
  • Fig. 19 Related/ancillary market outlook
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 25 Large Molecule Drug Substance CDMO market service outlook: Segment Dashboard
  • Fig. 26 Large Molecule Drug Substance CDMO market: Service movement analysis
  • Fig. 27 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 28 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 29 Commercial market, 2018 - 2030 (USD Million)
  • Fig. 30 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 31 Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 32 Process Development market, 2018 - 2030 (USD Million)
  • Fig. 33 35 Large Molecule Drug Substance CDMO market source outlook: Segment Dashboard
  • Fig. 34 Large Molecule Drug Substance CDMO market: Source movement analysis
  • Fig. 35 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 36 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 37 Others market, 2018 - 2030 (USD Million)
  • Fig. 38 Large Molecule Drug Substance CDMO market end-user outlook: Segment Dashboard
  • Fig. 39 Large Molecule Drug Substance CDMO market: End-User movement analysis
  • Fig. 40 Biotech Companies market, 2018 - 2030 (USD Million)
  • Fig. 41 CRO market, 2018 - 2030 (USD Million)
  • Fig. 42 Others (Pharma companies, Government, Research Institutes, Academic Institutes, Etc
  • Fig. 43 Regional market place: Dashboard
  • Fig. 44 Large Molecule Drug Substance CDMO Market: Definition & Scope
  • Fig. 45 Regional Market Snapshot (Figures in USD Million, 2022)
  • Fig. 46 Regional Market Share, 2022 (USD Million)
  • Fig. 47 Regional outlook, 2022& 2030
  • Fig. 48 North America market, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. market, 2018 - 2030 (USD Million
  • Fig. 50 Canada market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market, 2018 - 2030 (USD Million)
  • Fig. 52 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 53 Germany market, 2018 - 2030 (USD Million)
  • Fig. 54 France market, 2018 - 2030 (USD Million)
  • Fig. 55 Italy market, 2018 - 2030 (USD Million)
  • Fig. 56 Spain market, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark market, 2018 - 2030 (USD Million)
  • Fig. 59 Norway market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan market, 2018 - 2030 (USD Million)
  • Fig. 62 China market, 2018 - 2030 (USD Million)
  • Fig. 63 India market, 2018 - 2030 (USD Million)
  • Fig. 64 Australia market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 66 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 69 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 71 MEA market, 2018 - 2030 (USD Million)
  • Fig. 72 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 74 UAE market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait market, 2018 - 2030 (USD Million)